文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

肾移植候选者前列腺癌放疗:移植特异性危及器官的规划框架

Prostate cancer radiotherapy in kidney transplant candidates: a planning framework for defining and optimizing transplant-specific organs at risk.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-05-15

本研究通过多学科协作定义移植关键结构(膀胱顶、输尿管、髂血管周围脂肪),并在两种膀胱体积下比较六种规划策略的剂量学影响。结果显示,仅前列腺放疗时主动优化可使移植特异性危及器官平均剂量降低三倍以上且不牺牲靶区覆盖;而骨盆淋巴结照射时优化无法有效降低剂量,多种结构平均剂量超过20 Gy。

要点

  • 仅前列腺放疗时,主动优化移植特异性危及器官可显著降低剂量而不影响靶区覆盖。
  • 骨盆淋巴结照射时,即使优化,移植关键结构平均剂量仍超过20 Gy。
  • SBRT对移植特异性危及器官的绝对剂量最低。

核心结论

  • 仅前列腺放疗可通过主动优化有效保护移植关键结构,而骨盆淋巴结照射不可避免使这些结构接受高剂量。

研究设计与样本

  • 通过放射肿瘤科与移植外科多学科协作识别并勾画移植关键结构,在两种膀胱体积下对六种规划策略进行比较剂量学分析。

主要发现

  • 仅前列腺IMRT主动优化移植特异性危及器官可使膀胱顶平均剂量降低三倍或以上,且不损害靶区覆盖或不增加常规危及器官剂量。
  • 输尿管和髂血管周围外脂肪也观察到类似剂量降低。
  • SBRT对所有移植特异性危及器官达到最低绝对剂量。
  • 包含骨盆淋巴结时优化未能有意义地降低剂量,多个移植关键结构平均剂量超过20 Gy。

关键数值与推荐

  • 仅前列腺治疗中主动优化使膀胱顶平均剂量降低三倍或以上。
  • 骨盆淋巴结照射时多个移植关键结构平均剂量超过20 Gy。

临床怎么用

  • 对肾移植候选者前列腺癌放疗应采用移植导向的治疗规划,主动优化移植特异性危及器官。
  • 应谨慎选择骨盆淋巴结照射,因其不可避免使移植关键结构接受高剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Kidney transplant candidates increasingly present with localized or locally advanced prostate cancer. While radiotherapy is frequently indicated, current planning guidelines do not account for the surgical constraints of future kidney transplantation. This study proposes a practical planning framework by defining transplant-specific organs at risk (OARs) and evaluating the dosimetric impact of their systematic optimization during prostate cancer radiotherapy. MATERIALS AND METHODS: Through multidisciplinary collaboration between radiation oncologists and transplant surgeons, transplantation-critical structures were identified and delineated, including the bladder dome, ureters, and peri-vascular iliac fat. A comparative dosimetric analysis was performed across six planning strategies applied to two representative anatomical situations reflecting different bladder volumes: prostate-only Intensity Modulated Radiation Therapy (IMRT) with and without transplant-specific OARs optimization, stereotactic body radiotherapy (SBRT), and prostate plus pelvic nodal IMRT with and without optimization. Dose metrics to transplant-specific and conventional OARs were analyzed. RESULTS: In prostate-only treatments, active optimization of transplant-specific OARs resulted in a threefold or greater reduction in mean dose to the bladder dome, without compromising target coverage or increasing doses to conventional OARs. Similar dose reductions were observed for ureters and peri-vascular iliac external fat. SBRT achieved the lowest absolute doses to all transplant-specific OARs. In contrast, when pelvic lymph nodes were included, optimization failed to meaningfully reduce doses, with mean values exceeding 20 Gy for several transplant-critical structures. CONCLUSION: This work establishes a planning framework for integrating kidney transplantation constraints into prostate cancer radiotherapy. Prostate-only radiotherapy allows effective sparing of transplant-critical structures through active optimization, whereas pelvic nodal irradiation inevitably exposes these structures to high doses despite optimization. These findings support transplant-oriented treatment planning and careful selection of pelvic irradiation in kidney transplant candidates.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Gueiderikh A, Panis A, Klotz S, et al. Prostate cancer radiotherapy in kidney transplant candidates: a planning framework for defining and optimizing transplant-specific organs at risk. Clin Transl Radiat Oncol. 2026. PMID: 42211346. doi:10.1016/j.ctro.2026.101186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。